Janux Therapeutics (NASDAQ:JANX) Receives “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Janux Therapeutics (NASDAQ:JANX) in a report published on Monday, Benzinga reports. Cantor Fitzgerald currently has a $100.00 price target on the stock.

Several other research analysts have also recently issued reports on the stock. Wedbush reiterated an outperform rating and issued a $74.00 price objective on shares of Janux Therapeutics in a report on Thursday, August 8th. Scotiabank reduced their target price on shares of Janux Therapeutics from $47.00 to $42.00 and set a sector perform rating for the company in a report on Friday, August 9th. HC Wainwright restated a buy rating and set a $63.00 target price on shares of Janux Therapeutics in a report on Monday, August 19th. Finally, Stifel Nicolaus started coverage on shares of Janux Therapeutics in a report on Friday, September 6th. They set a buy rating and a $70.00 target price for the company. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, Janux Therapeutics currently has an average rating of Moderate Buy and a consensus target price of $66.13.

Janux Therapeutics Price Performance

Janux Therapeutics stock opened at $49.89 on Monday. The firm has a 50 day simple moving average of $42.99 and a 200-day simple moving average of $44.15. The stock has a market capitalization of $2.59 billion, a PE ratio of -40.89 and a beta of 3.57. Janux Therapeutics has a 12-month low of $5.65 and a 12-month high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.20. The business had revenue of $8.90 million during the quarter, compared to analysts’ expectations of $0.77 million. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. Janux Therapeutics’s revenue for the quarter was up 709.1% compared to the same quarter last year. On average, analysts forecast that Janux Therapeutics will post -1.18 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $42.00, for a total value of $4,551,330.00. Following the completion of the transaction, the insider now owns 3,162,851 shares of the company’s stock, valued at approximately $132,839,742. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders sold 268,578 shares of company stock valued at $12,071,151. Company insiders own 35.40% of the company’s stock.

Institutional Investors Weigh In On Janux Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Capstone Investment Advisors LLC purchased a new stake in Janux Therapeutics in the 1st quarter worth approximately $1,969,000. Janus Henderson Group PLC raised its holdings in shares of Janux Therapeutics by 1.8% during the 1st quarter. Janus Henderson Group PLC now owns 1,965,546 shares of the company’s stock valued at $73,961,000 after purchasing an additional 34,069 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new position in shares of Janux Therapeutics during the 1st quarter valued at $739,000. Virtu Financial LLC bought a new position in shares of Janux Therapeutics during the 1st quarter valued at $609,000. Finally, Vanguard Group Inc. raised its holdings in shares of Janux Therapeutics by 38.6% during the 1st quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock valued at $51,127,000 after purchasing an additional 378,477 shares in the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.